Fernández-Villar Alberto, Leiro Virginia, Blanco Monserrat, Represas Cristina, Botana Maribel, González Ana, Piñeiro Luis
Department of Pulmonary Diseases, Xeral Hospital-Cíes, Vigo, Spain.
Respiration. 2007;74(2):208-13. doi: 10.1159/000097496. Epub 2006 Nov 23.
Several different types of needles for transbronchial needle aspiration (TBNA) exist in the market. Recently, the eXcelon transbronchial needle (Boston Scientific, Boston, Mass., USA) was commercialized, and to our knowledge, no comparative studies with other types of needles have been performed up to date.
The aim of the present study was to determine the diagnostic yield and safety of the 21-gauge eXcelon transbronchial needle in the diagnosis of mediastinal lesions and to compare it with a 22-gauge Wang cytology needle (Bard-Wang, Billerica, Mass., USA).
A case-control prospective study was conducted. The study group included 42 TBNA of mediastinal nodes performed in 35 patients with the eXcelon 21-gauge needle from January to June 2005. A control group included 110 TBNA carried out in 99 patients that underwent mediastinal lymph node sampling using a MW-122 needle from June 2002 to December 2004.
There was no statistical differentiation in the characteristics of the disease, mediastinal lymph nodes or number of passes between cases and controls. Adequate samples were obtained in 30 (71.4%) cases and 81 (73.6%) controls (p = 0.8). Technical complications occurred in 7 (16.6%) cases and 14 (12.7%) controls (p = 0.7). The only clinical complication was bleeding presented in 2 (4.8%) cases and 3 (2.7%) controls (p = 0.3).
The eXcelon 21-gauge transbronchial needle is as effective and safe as the MW-122 needle in the diagnosis of mediastinal lymph node enlargement.
市场上存在几种不同类型的用于经支气管针吸活检（TBNA）的针。最近，eXcelon经支气管针（美国马萨诸塞州波士顿市波士顿科学公司）已商业化，据我们所知，迄今为止尚未进行与其他类型针的比较研究。
本研究的目的是确定21号eXcelon经支气管针在纵隔病变诊断中的诊断率和安全性，并将其与22号王氏细胞学针（美国马萨诸塞州比勒里卡市巴德 - 王氏公司）进行比较。
进行了一项病例对照前瞻性研究。研究组包括2005年1月至6月期间使用21号eXcelon针在35例患者中对纵隔淋巴结进行的42次TBNA。对照组包括2002年6月至2004年12月期间在99例患者中使用MW - 122针进行纵隔淋巴结采样的110次TBNA。
病例组和对照组在疾病特征、纵隔淋巴结或穿刺次数方面无统计学差异。30例（71.4%）病例和81例（73.6%）对照组获得了足够的样本（p = 0.8）。7例（16.6%）病例和14例（12.7%）对照组发生了技术并发症（p = 0.7）。唯一的临床并发症是出血，2例（4.8%）病例和3例（2.7%）对照组出现出血（p = 0.3）。
21号eXcelon经支气管针在诊断纵隔淋巴结肿大方面与MW - 122针一样有效和安全。
